Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Biocon Ltd (BIOCON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9873)・商品コード:DATA904C9873
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:87
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,750見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions like cancer, diabetes and autoimmune. The company produces a wide range of active pharmaceutical ingredients (APIs), branded formulations; and complex biologics both novels and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. It also provides research services including discovery, development and manufacturing services for both small and large molecules. Biocon provides research solutions to the biotechnology and pharmaceutical companies worldwide. It has an overseas manufacturing facility at BioXcell, a biotechnology park in Johor, Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd (BIOCON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Ltd, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Venture Financing 16
Syngene May Raise Over USD50 Million in Venture Financing 16
Private Equity 17
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Partnerships 22
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Licensing Agreements 34
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Equity Offering 42
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Asset Transactions 45
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd – Key Competitors 46
Biocon Ltd – Key Employees 47
Biocon Ltd – Locations And Subsidiaries 48
Head Office 48
Other Locations & Subsidiaries 48
Joint Venture 48
Recent Developments 50
Strategy And Business Planning 50
Aug 11, 2017: Biocon Announces Incorporation of a Wholly Owned Subsidiary in Malaysia 50
Financial Announcements 51
Oct 25, 2018: Biocon announces financial results for the second quarter ended on September 30th, 2018 51
Jul 26, 2018: Biocon Q1FY19 revenue Rs 1,193 Cr, Up 21%; EBITDA up 25% at Rs 307 Cr; net profit up 47% at Rs 120 Cr 54
Apr 26, 2018: Biocon Q4FY18 Revenue Rs 1,237 Cr, Up 27%; EBITDA Up 30% at Rs 300 Cr; Net Profit Up 2% at Rs 130 Cr[TOPC : Pharma - Biocon Ltd] 57
Oct 26, 2017: Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore 60
Jul 27, 2017: Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore 63
Apr 27, 2017: Biocon Q4 FY17 Revenue Rs 974 Cr; Net Profit Rs 127 Cr; FY17 Revenue at Rs 4,079 Cr; Net Profit at Rs 612 Cr 67
Jan 24, 2017: Biocon Q3 FY17 Net Profit Up 65% at Rs 171 Crore 70
Legal and Regulatory 73
Sep 22, 2018: Biocon’s drug substance facility in bangalore completes US FDA inspection with No observations 73
Jul 04, 2018: Biocon’s Sterile Drug Product facility Receives EU GMP Certification 74
Jun 23, 2018: Biocon’s Sterile Drug Product facility Receives EIR from U.S. FDA 75
May 02, 2018: Biocon Regulatory Audit Update 76
Mar 13, 2018: Update On Company Statement On US-FDA Inspection At Biocon Malaysia 77
Feb 21, 2018: Biocon Announces US-FDA Inspection at Malaysian Manufacturing Facility 78
Nov 20, 2017: Biocon’s Drug product Facility Receives EIR with VAI status, Inspection Closed 79
Sep 18, 2017: Biocon’s Facility in Vishakhapatnam completes USFDA Inspection with no observations 80
Jul 09, 2017: Biocon provides update on Bangalore Facility 81
Jul 09, 2017: Biocon: Update on Inspection Audits by French health agency 82
May 10, 2017: Biocon statement in response to media reports on USFDA Form 483s for Biocon Limited 83
Other Significant Developments 84
Dec 13, 2017: Biocon’s Clarification post media reports on “Biocon on the FDA list for not paying facility fee” 84
Oct 06, 2017: Biocon: No Separate Audit or Observations by Health Canada 85
May 05, 2017: Biocon: Company Statement Media Reports on USFDA 483s 86
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87

List of Tables
Biocon Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11
Biocon Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Biocon Biologics India to Acquire Biosimilars Business from Biocon 14
Biocon Acquires Pharma Manufacturing Unit from Acacia Life Sciences 15
Syngene May Raise Over USD50 Million in Venture Financing 16
Silver Leaf Oak Acquires 10% Stake in Syngene International from Biocon Research for USD62.2 Million 17
IVF Trustee Acquires 10% Stake in Syngene International for USD62 Million 19
GE Equity International Mauritius Completes Acquisition Of 7.69% Stake In Syngene International For US$23 Million 20
Mylan Enters Into Licensing Agreement With Biocon For Three Generic Insulin Products 22
Artelo Biosciences Enters into Agreement with Syngene International and Aptus Clinical 23
Syngene International Enters into Agreement with Zumutor Biologics 24
Sandoz International Enters into Agreement with Biocon 25
Biocon Enters into Agreement with Juvenile Diabetes Research Foundation 26
Biocon Enters into Co-Development Agreement with Laboratorios PiSA 27
Saniona Enters into Agreement with Syngene 28
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 29
CytoSorbents Expands Co-Marketing Agreement with Biocon 30
Biocon On The Lookout For Partners To Develop And Market Psoriasis Drug Itolizumab 31
Biocon Plans To Enter Into Co-Development Agreement For Biosimilars 32
Abbott India Enters Into Joint Venture Agreement With Syngene International 33
Equillium Enters into Licensing Agreement with Biocon 34
Advaxis Enters Into Licensing Agreement With Biocon For ADXS-HPV 36
Biocon Enters Into Licensing Agreement With CCM Pharma For Insulin Products 38
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 39
Biocon Enters into Licensing Agreement with Gilead Sciences 40
Biocon And Quark Pharma Enter Into Agreement To Develop siRNA Based Therapeutics 41
Biocon May Raise up to USD500 Million in Public Offering 42
Syngene International Raises up to USD86 Million in IPO 43
Biocon Biologics India to Acquire Biosimilars Business from Biocon 45
Biocon Ltd, Key Competitors 46
Biocon Ltd, Key Employees 47
Biocon Ltd, Subsidiaries 48
Biocon Ltd, Joint Venture 48

List of Figures
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Biocon Ltd, Medical Devices Deals, 2012 to YTD 2018 11

★調査レポート[Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9873)販売に関する免責事項を必ずご確認ください。
★調査レポート[Biocon Ltd (BIOCON):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆